In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leela Barham

Latest From Leela Barham

Mixed Support For ABPI's UK Price Scheme Proposals

The UK pharma industry body has set out bold proposals for a new drug pricing agreement from 2024, but not everyone is convinced. Generics companies are pressing for more of a say in the negotiations, while patient groups want to know more about how the deal would help improve access to medicines.

Europe United Kingdom

Pharma Firms May Be Due A Refund Under UK Voluntary Price Scheme

Companies that chose to stay in the UK’s voluntary pricing scheme (VPAS) could be entitled to a refund on their rebate payments, while those that have left may end up paying more.

Pricing Debate Regulation

Former NICE Exec Proposes New UK Fund For ‘High-Impact’ Drugs

Some of the rebates paid by drug companies to the government on their sales of medicines could be placed in a central fund to pay for drugs of “demonstrable benefit,” according to Andrew Dillon.

Europe United Kingdom

Freezing UK Statutory Scheme Rebate Could Cost UK Government Over £15m

Accepting the pharmaceutical industry’s request to keep the statutory scheme rebate rate at its current rate this year could cost the government dearly, but raising it as planned could be detrimental for UK life sciences.

Europe United Kingdom

Looking Beyond The Deal In England

Agreement of deals that promise better value for money and enhanced patient access to new treatments has become routine in England, but are they delivering?

Deals Commercial

Next UK Drug Pricing Scheme Needs ‘Single-Digit Fixed Rebates’

The pharmaceutical industry and the UK government are beginning a series of discussions on the shape of the future voluntary drug pricing and access scheme (VPAS), ahead of the formal negotiations that are scheduled to start in April.

Europe United Kingdom
See All
UsernamePublicRestriction

Register